Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mongersen - Celgene Corporation

Next Previous
X
Search
Drug Profile

Mongersen - Celgene Corporation

Alternative Names: GED-0301

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Giuliani
  • Developer Celgene Corporation
  • Class Anti-inflammatories; Antisense oligonucleotides
  • Mechanism of Action Smad7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in United Kingdom (PO)
  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 15 Mar 2018 Celgene terminates a phase I trial following a recommendation from external DMC to terminate the ongoing phase III CD studies in Crohn's disease in USA, Canada, Slovakia, Hungary and Australia (PO) (NCT02367183)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top